8-K: RenovoRx Reports Initial RenovoCath Revenues and Provides TIGeR-PaC Trial Update

RenovoRx announces initial revenues from RenovoCath commercialization, provides an update on the TIGeR-PaC clinical trial, and reports its 2024 financial results, including a $7.2 million cash position and $12.1 million in gross proceeds from a February 2025 offering.

Summary

• RenovoRx reported its first revenue from RenovoCath sales in Q4 2024, totaling approximately $43,000.
• The company anticipates sequential revenue growth from RenovoCath throughout 2025.
• RenovoRx expects to complete enrollment in the TIGeR-PaC clinical trial and review the second interim analysis by the Data Monitoring Committee in 2025.
• The company's cash position as of December 31, 2024, was $7.2 million, supplemented by $12.1 million in gross proceeds from a February 2025 public offering.
• Research and development expenses for 2024 were $6.0 million, while selling, general, and administrative expenses were $5.0 million.
• The net loss for 2024 was $8.8 million.
• RenovoRx estimates the initial total addressable market for RenovoCath to be $400 million in peak annual U.S. sales, with potential for expansion into a multi-billion dollar market.
• As of March 25, 2025, there were 36,546,752 shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the initial revenue generation and progress in the clinical trial, but tempered by the net loss and ongoing risks associated with clinical development and commercialization.

Positives

• RenovoRx has generated initial revenues from RenovoCath sales, marking a significant milestone.
• The company anticipates sequential revenue growth from RenovoCath throughout 2025.
• RenovoRx has a strong cash position, bolstered by a recent public offering.
• The TIGeR-PaC trial is progressing, with patient enrollment continuing.
• RenovoCath has a substantial total addressable market, with potential for further expansion.
• The company is expanding its intellectual property portfolio.

Negatives

• The company reported a net loss of $8.8 million for the year ended December 31, 2024.
• The TIGeR-PaC trial requires 86 events (deaths) necessary to complete the final analysis, and as of March 28, 2025, 50 events have occurred, indicating the trial is event-driven and dependent on patient outcomes.

Risks

• The company's ability to achieve revenue growth from RenovoCath sales is subject to market adoption and competition.
• The TIGeR-PaC trial's outcome is uncertain, and interim results may not be predictive of final results.
• Regulatory authorities may disagree with the company's interpretation of clinical trial data.
• The company's future success depends on its ability to obtain regulatory approvals for its product candidates.
• The company may require additional financing in the future to fund its operations.

Future Outlook

RenovoRx expects sequential revenue growth from RenovoCath throughout 2025 and anticipates completing enrollment in the TIGeR-PaC clinical trial and reviewing the second interim analysis by the Data Monitoring Committee in 2025.

Management Comments

• Shaun Bagai, CEO of RenovoRx, stated that the company's current commercial strategy can be accomplished without a material increase in capital expenditures.
• Mr. Bagai also mentioned that the gross proceeds from the February 2025 public offering, together with the cash on hand, fully funds the company's current operational plan.
• Mr. Bagai believes that growing RenovoCath revenues will reduce the company's burn rate.

Industry Context

RenovoRx is operating in the targeted oncology therapies and drug delivery device market, competing with companies developing similar technologies for local drug delivery. The company's RenovoCath device and TAMP therapy platform aim to improve the safety and efficacy of cancer treatments by delivering drugs directly to the tumor site.

Comparison to Industry Standards

• The company estimates the initial total addressable market (TAM) for RenovoCath represents an estimated $400 million peak annual U.S. sales opportunity, based on internal analysis with current clinical applications.
• The company believes that the twenty cancer centers that have used RenovoCath as part of its TIGeR-PaC trial could also be potential customers for RenovoCath after completion of TIGeR-PaC enrollment later this year.
• The company's management believes that the Company can achieve meaningful market penetration with a small commercial team targeting the top 200 high-volume treatment centers.

Stakeholder Impact

• Shareholders may be positively impacted by the initial revenue generation and clinical trial progress.
• Employees are likely to be impacted by the company's commercialization efforts and clinical development activities.
• Cancer patients may benefit from the potential of RenovoCath and the TAMP therapy platform to improve treatment outcomes.
• Customers (medical institutions) are being targeted for RenovoCath purchase orders.
• Suppliers and manufacturers are impacted by the company's need to scale production to meet anticipated demand.

Next Steps

• RenovoRx will continue to scale RenovoCath revenues.
• The company will progress its Phase III TIGeR-PaC clinical trial towards key milestones.
• RenovoRx will host a fireside chat on April 3, 2025, to discuss commercialization efforts and clinical trial progress.
• The company will continue to target additional clinical oncology sites to support patient enrollment for the TIGeR-PaC trial.
• RenovoRx will actively explore further revenue-generating activity either on its own or in tandem with a medical device commercial partner.

Key Dates

Keywords

RenovoRx, RenovoCath, TIGeR-PaC, Clinical Trial, Revenue, Financial Results, Oncology, Drug Delivery, LAPC, TAMP